source
- Replimune secures FDA approval for RP1 therapy in advanced melanoma as Eli Lilly reports strong Q2 earningsReplimune announced that the FDA has granted market approval for its oncolytic immunotherapy RP1, aimed at treating advanced melanoma. The decision follows two earlier rejections and a contentious…
- Experts warn of deaths linked to Neurocrine's Vykat XR for Prader-Willi syndromeA coalition of specialists in Prader-Willi syndrome has raised serious concerns about the safety profile of Neurocrine Biosciences' drug Vykat XR. The experts point to a series of adverse events,…